251 related articles for article (PubMed ID: 16189139)
1. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration.
Edstein MD; Kotecka BM; Anderson KL; Pombo DJ; Kyle DE; Rieckmann KH; Good MF
Antimicrob Agents Chemother; 2005 Oct; 49(10):4421-2. PubMed ID: 16189139
[No Abstract] [Full Text] [Related]
2. Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro.
Butcher GA; Sinden RE
Am J Trop Med Hyg; 2003 Jan; 68(1):111-4. PubMed ID: 12556158
[TBL] [Abstract][Full Text] [Related]
3. [Mechanism of action of antimalarials. Value of combined atovaquone/proguanil].
Touze JE; Fourcade L; Pradines B; Hovette P; Paule P; Heno P
Med Trop (Mars); 2002; 62(3):219-24. PubMed ID: 12244914
[TBL] [Abstract][Full Text] [Related]
4. [Clinical studies using the combination atovaquone-proguanil as malaria prophylaxis in non-immune adult and child travelers].
Camus D; Dutoit E; Masson V; Inglebert P; Delhaes L
Med Trop (Mars); 2002; 62(3):225-8. PubMed ID: 12244915
[TBL] [Abstract][Full Text] [Related]
5. [What is the value of the combination atovaquone-proguanil for the clinician?].
Delmont J
Med Trop (Mars); 2002; 62(3):232-6. PubMed ID: 12244917
[TBL] [Abstract][Full Text] [Related]
6. Atovaquone/proguanil resistance in Africa: a case report.
David KP; Alifrangis M; Salanti A; Vestergaard LS; Rønn A; Bygbjerg IB
Scand J Infect Dis; 2003; 35(11-12):897-8. PubMed ID: 14723376
[TBL] [Abstract][Full Text] [Related]
7. [Experience with the combination atovaquone-proguanil in the treatment of uncomplicated Plasmodium falciparum malaria--report of 112 cases].
Malvy D; Djossou F; Vatan R; Pistone T; Etienne G; Longy-Boursier M; Le Bras M
Med Trop (Mars); 2002; 62(3):229-31. PubMed ID: 12244916
[TBL] [Abstract][Full Text] [Related]
8. Atovaquone/Proguanil (Malarone) for malaria.
Med Lett Drugs Ther; 2000 Nov; 42(1093):109-11. PubMed ID: 11093830
[No Abstract] [Full Text] [Related]
9. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa.
Kuhn S; Gill MJ; Kain KC
Am J Trop Med Hyg; 2005 Apr; 72(4):407-9. PubMed ID: 15827276
[TBL] [Abstract][Full Text] [Related]
10. Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate.
Gupta RK; Van Vugt M; Paiphun L; Slight T; Looareesuwan S; White NJ; Nosten F
Am J Trop Med Hyg; 2005 Aug; 73(2):267-8. PubMed ID: 16103586
[TBL] [Abstract][Full Text] [Related]
11. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers.
Musset L; Pradines B; Parzy D; Durand R; Bigot P; Le Bras J
J Antimicrob Chemother; 2006 Jan; 57(1):110-5. PubMed ID: 16319183
[TBL] [Abstract][Full Text] [Related]
12. Atovaquone-proguanil for prophylaxis and treatment of malaria.
Marra F; Salzman JR; Ensom MH
Ann Pharmacother; 2003 Sep; 37(9):1266-75. PubMed ID: 12921511
[TBL] [Abstract][Full Text] [Related]
13. In vitro recrudescence of Plasmodium falciparum parasites suppressed to dormant state by atovaquone alone and in combination with proguanil.
Thapar MM; Gil JP; Björkman A
Trans R Soc Trop Med Hyg; 2005 Jan; 99(1):62-70. PubMed ID: 15550263
[TBL] [Abstract][Full Text] [Related]
14. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia.
Ling J; Baird JK; Fryauff DJ; Sismadi P; Bangs MJ; Lacy M; Barcus MJ; Gramzinski R; Maguire JD; Kumusumangsih M; Miller GB; Jones TR; Chulay JD; Hoffman SL;
Clin Infect Dis; 2002 Oct; 35(7):825-33. PubMed ID: 12228819
[TBL] [Abstract][Full Text] [Related]
15. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe.
Wichmann O; Muehlberger N; Jelinek T; Alifrangis M; Peyerl-Hoffmann G; Muhlen M; Grobusch MP; Gascon J; Matteelli A; Laferl H; Bisoffi Z; Ehrhardt S; Cuadros J; Hatz C; Gjorup I; McWhinney P; Beran J; da Cunha S; Schulze M; Kollaritsch H; Kern P; Fry G; Richter J;
J Infect Dis; 2004 Nov; 190(9):1541-6. PubMed ID: 15478057
[TBL] [Abstract][Full Text] [Related]
16. Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.
Lacy MD; Maguire JD; Barcus MJ; Ling J; Bangs MJ; Gramzinski R; Basri H; Sismadi P; Miller GB; Chulay JD; Fryauff DJ; Hoffman SL; Baird JK
Clin Infect Dis; 2002 Nov; 35(9):e92-5. PubMed ID: 12384852
[TBL] [Abstract][Full Text] [Related]
17. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa.
Schwartz E; Bujanover S; Kain KC
Clin Infect Dis; 2003 Aug; 37(3):450-1. PubMed ID: 12884171
[TBL] [Abstract][Full Text] [Related]
18. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro.
Canfield CJ; Pudney M; Gutteridge WE
Exp Parasitol; 1995 May; 80(3):373-81. PubMed ID: 7729473
[TBL] [Abstract][Full Text] [Related]
19. Atovaquone/proguanil for the prophylaxis and treatment of malaria.
Patel SN; Kain KC
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):849-61. PubMed ID: 16307498
[TBL] [Abstract][Full Text] [Related]
20. Direct comparison of antimalarial activity among PS-15 combination therapies by bioassay of serum samples from treated Saimiri sciureus.
Yeo AE
J Parasitol; 1997 Jun; 83(3):515-8. PubMed ID: 9194836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
